MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Parkinson’s Disease-Related Pattern in isolated REM Sleep Behavior Disorder as a prodromal progression marker

    G. Carli, S. Meles, A. Dortmond, A. Janzen, E. Sittig, E. de Meyer, K. Leenders, W. Oertel (Groningen, Netherlands)

    Objective: To investigate expression of the PD-related pattern in 18F-FDG PET scans of iRBD patients longitudinally. Background: The Parkinson’s disease-related pattern (PDRP) might serve as…
  • 2024 International Congress

    Prediction of The Monopolar Review in Deep Brain Stimulation for Parkinson’s Disease using Imaging

    V. Lavu, M. Godhala, T. Batchali, S. Aghili-Mehrizi, J. Wong (Gainesville, USA)

    Objective: To build an AI model that can predict the monopolar review in deep brain stimulation (DBS) for Parkinson’s disease (PD) based on imaging. Background:…
  • 2024 International Congress

    Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center

    B. Delsaut, V. Leclercq, S. Dethy (La Louvière, Belgium)

    Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…
  • 2024 International Congress

    Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease

    Z. Wang, R. Gomeni, R. Pahwa, R. Hauser, A. Formella, M. Grall, H. Upadhyaya, J. Rubin (Rockville, USA)

    Objective: Evaluate pharmacokinetic/pharmacodynamic (PK/PD) relationships for the delayed- and extended-release (DR/ER) capsule formulation of amantadine [1] in the treatment of levodopa-related dyskinesia in Parkinson disease.…
  • 2024 International Congress

    One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

    V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)

    Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…
  • 2024 International Congress

    Deep brain stimulation contact selection using Neurophysiology and Artificial intelligence

    V. Lavu, J. Cagle, T. de Araujo, C. de Hemptinne, J. Wong (Gainesville, USA)

    Objective: To develop a machine learning (ML) algorithm capable of predicting the optimal deep brain stimulation (DBS) contact based on neurophysiology. Background: DBS is an…
  • 2024 International Congress

    Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease

    T. Yamamoto, Y. Yamanaka, S. Hirano, A. Sugiyama, N. Araki, Y. Higuchi, S. Kuwabara (Chiba, Japan)

    Objective: To clarify longitudinal changes in QOL in PD after STN-DBS. Background: While it is well known that motor complications are dramatically improved after subthalamic…
  • 2024 International Congress

    Long term evaluation of gluten-free diet in Parkinson´s disease patients

    H. Brožová, K. Poláková, T. Gentileová, M. Fialová, M. Kubjatková, J. Rusz, M. Sap, M. Kuzma, H. Pelantová, M. Jandová, D. Funda (Prague, Czech Republic)

    Objective: The primary aim of the project was to evaluate the effect of long-term administered gluten-free diet (GFD) on motor symptoms of Parkinson's disease (PD).…
  • 2024 International Congress

    Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact

    C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez (Monterrey, Mexico)

    Objective: These preliminary study aims to describe the primary clinical features of Parkinson's disease patients requiring palliative care, as assessed by the Edmonton Symptom Assessment…
  • 2024 International Congress

    Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.

    D. Rivero-Rodríguez, M. Morales-Casado, G. Tabar-Comellas, A. Diezma-Martín, P. Quintana-Castro, M. Ennazeh, N. López-Ariztegui (Toledo, Spain)

    Objective: To determine the clinical characteristics associated with early withdrawal of Levodopa-Carbidopa Intestinal Gel infusion (LCIG) in patients with advanced Parkinson´s Disease (APD) Background: LCIG…
  • « Previous Page
  • 1
  • …
  • 480
  • 481
  • 482
  • 483
  • 484
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley